CoQ10 vs PQQ
Two mitochondrial-support supplements often stacked together — one with a positive heart-failure mortality trial, the other with a strong biogenesis mechanism and thinner human outcome data.
Short answer
CoQ10 and PQQ are both over-the-counter supplements with human trial data, so the choice comes down to your goal. CoQ10 suits someone focused on heart failure (as an adjunct), statin-myopathy relief, migraine prevention and general anti-aging, while PQQ is aimed at mitochondrial biogenesis and cognitive and cardiovascular support.
CoQ10
Coenzyme Q10, ubiquinone, ubiquinol
Q-SYMBIO showed a real reduction in cardiovascular mortality and hospitalization when added to standard heart-failure therapy — a hard outcome, not a surrogate. Migraine prevention data are real but more modest; statin-myopathy relief did not beat placebo in meta-analysis. The 'declines with age, so restore it' pitch aimed at healthy adults has no supporting outcome trial.
Full CoQ10 evidence reviewPQQ
Pyrroloquinoline quinone
A genuine mitochondrial-biogenesis signal in cell and animal models, with a small number of short human trials on cognition and inflammation markers — promising mechanism, thin human outcome data.
Full PQQ evidence reviewCoQ10 vs PQQ: head to head
- FDA status / approved use
CoQ10
Sold as a supplementPQQ
Sold as a dietary supplement, not a treatment- Marketed for
CoQ10
Heart failure adjunct, statin-myopathy relief, migraine prevention, general anti-aging 'energy'PQQ
Mitochondrial biogenesis, cognitive and cardiovascular support- Outcome areas
CoQ10
Cardiovascular; Mitochondrial / cellular energy; Longevity / lifespanPQQ
Mitochondrial / cellular energy; Cognitive function / memory; Cardiovascular- Evidence grade
CoQ10
Clinical dataPQQ
Clinical data- How it works
CoQ10
Shuttles electrons in the mitochondrial respiratory chain and acts as an antioxidantPQQ
Activates the CREB–PGC-1α pathway that triggers new mitochondria in lab studies- Route and dosing
CoQ10
Oral supplement; 100 mg three times daily in the heart failure trialPQQ
Oral supplement, typically about 20 mg daily- Headline human result
CoQ10
Reduced major adverse cardiovascular events and mortality in chronic heart failure in the Q-SYMBIO randomized trialPQQ
Improved selective attention on a Stroop task at 20 mg/day over 12 weeks in a 2016 RCT of 41 older adults- Strongest evidence
CoQ10
Q-SYMBIO, JACC Heart Failure 2014CoQ10 evidence reviewPubMed 25282031PQQ
Mitochondrial biogenesis mechanism, J Biol Chem 2010PQQ evidence reviewPubMed 19861415- Key safety signal
CoQ10
Well tolerated, with mostly mild gastrointestinal effects at typical dosesPQQ
Generally well tolerated around 20 mg/day; no long-term trials- How it is obtained
CoQ10
Over the counter as a dietary supplementPQQ
Over the counter as a dietary supplement
| CoQ10 | PQQ | |
|---|---|---|
| FDA status / approved use | Sold as a supplement | Sold as a dietary supplement, not a treatment |
| Marketed for | Heart failure adjunct, statin-myopathy relief, migraine prevention, general anti-aging 'energy' | Mitochondrial biogenesis, cognitive and cardiovascular support |
| Outcome areas | Cardiovascular; Mitochondrial / cellular energy; Longevity / lifespan | Mitochondrial / cellular energy; Cognitive function / memory; Cardiovascular |
| Evidence grade | Clinical data | Clinical data |
| How it works | Shuttles electrons in the mitochondrial respiratory chain and acts as an antioxidant | Activates the CREB–PGC-1α pathway that triggers new mitochondria in lab studies |
| Route and dosing | Oral supplement; 100 mg three times daily in the heart failure trial | Oral supplement, typically about 20 mg daily |
| Headline human result | Reduced major adverse cardiovascular events and mortality in chronic heart failure in the Q-SYMBIO randomized trial | Improved selective attention on a Stroop task at 20 mg/day over 12 weeks in a 2016 RCT of 41 older adults |
| Strongest evidence | Q-SYMBIO, JACC Heart Failure 2014CoQ10 evidence reviewPubMed 25282031 | Mitochondrial biogenesis mechanism, J Biol Chem 2010PQQ evidence reviewPubMed 19861415 |
| Key safety signal | Well tolerated, with mostly mild gastrointestinal effects at typical doses | Generally well tolerated around 20 mg/day; no long-term trials |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
CoQ10's Q-SYMBIO trial is the strongest human outcome data either compound has — a real reduction in cardiovascular mortality in heart-failure patients. PQQ's case is mechanistic: it genuinely stimulates mitochondrial biogenesis in cell and animal models, and the human trials that exist are small and short, testing cognition and inflammation markers rather than hard outcomes. They're frequently sold together on the theory that CoQ10 supports existing mitochondria while PQQ helps make new ones — a plausible combination story that has never itself been tested.
CoQ10 fits if
You want the compound with an actual positive human outcome trial behind it, particularly if heart failure or statin-related muscle symptoms are the concern.
PQQ fits if
You're drawn to the mitochondrial-biogenesis mechanism specifically and are comfortable with thinner, shorter human data.
CoQ10 vs PQQ: common questions
- Is either CoQ10 or PQQ FDA-approved?
- No. CoQ10 is sold as a supplement. PQQ is sold as a dietary supplement, not a treatment.
- Which has stronger human evidence, CoQ10 or PQQ?
- Neither clearly. Both have human clinical data. The key source for CoQ10 is Q-SYMBIO, JACC Heart Failure 2014; for PQQ, it is Mitochondrial biogenesis mechanism, J Biol Chem 2010.
- What are the main safety concerns with CoQ10 and PQQ?
- CoQ10 is well tolerated, with mostly mild gastrointestinal effects at typical doses. PQQ is generally well tolerated around 20 mg/day; no long-term trials.
Key studies behind each
CoQ10
- Mortensen SA, Rosenfeldt F, Kumar A, et al. (2014). The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. PubMed 25282031
- Banach M, Serban C, Sahebkar A, et al. (2015). Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. PubMed 25440725
- Sandor PS, Di Clemente L, Coppola G, et al. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. PubMed 15728298
- Kalen A, Appelkvist EL, Dallner G. (1989). Age-related changes in the lipid compositions of rat and human tissues. Lipids. PubMed 2779364
PQQ
- Chowanadisai W, Bauerly KA, Tchaparian E, et al. (2010). Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem. PubMed 19861415
- Liu L, Zhang Y, Liu T, et al. (2021). Pyrroloquinoline quinone protects against exercise-induced fatigue and oxidative damage via improving mitochondrial function in mice. FASEB J. PubMed 33710654
- Harris CB, Chowanadisai W, Mishchuk DO, et al. (2013). Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. J Nutr Biochem. PubMed 24231099
- Itoh Y, Hine K, Miura H, et al. (2016). Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ) on Cognitive Functions. Adv Exp Med Biol. PubMed 26782228
The full evidence reviews
- CoQ10: strong cardiac evidence, hype everywhere else
The Q-SYMBIO trial cut mortality in heart failure — but statin-muscle data are mixed, migraine support is moderate, and the anti-aging pitch rests on a decline, not an outcome.
Updated August 2026
- PQQ evidence: a strong mitochondrial mechanism, thin human data
PQQ activates the PGC-1α biogenesis pathway in the lab — but the human case is a few small, short, partly industry-run trials with no healthspan outcomes.
Updated August 2026